Drugs / Ad5-nCoV-IH
Ad5-nCoV-IH
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05330871 | Apr → Jun 2022 | COVID-19 | Seventh Medical Center of PLA General Hospital | Unknown | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05517642 | Sep 2022 → May 2023 | COVID-19 | CanSino Biologics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05169008 | Feb 2022 → Jan 2023 | COVID-19 | CanSino Biologics Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT05124561 | Dec 2021 → Apr 2022 | COVID-19 | CanSino Biologics Inc. | Withdrawn | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04952727 | Aug → Nov 2021 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04833101 Background | Apr → Sep 2021 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad5-nCoV-IH | “Ad5-nCoV-IH, 1 dose 0.1ml” NCT05330871 ↗ |
| Known as | AAd5 | “Heterologous booster immunisation with orally administered aerosolised Ad5-nCoV vaccine (AAd5) has been shown to be safe and highly immunogenic in adults.” PMID 37209700 ↗ May 2023 |
| Known as | Convidecia | “We aimed to assess the immunogenicity and safety of a heterologous immunisation with an adenovirus type 5-vectored vaccine (Ad5-nCOV, Convidecia) among elderly who were primed...” PMID 37360864 ↗ Jun 20232“with a recombinant adenovirus type-5-vectored Coronavirus Disease 2019 (COVID-19) vaccine (Convidecia, hereafter referred to as CV) and a protein-subunit-based COVID-19 vaccine...” PMID 35617368 ↗ May 2022 “receive a second booster dose of IH Convidecia vaccine (treatment arm)” NCT05517642 ↗ |
| Known as | IH Convidecia | “receive a second booster dose of IH Convidecia vaccine (treatment arm)” NCT05517642 ↗ |
| Known as | Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH) | “Biological: Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)” NCT05169008 ↗ |
| Modality | Vaccine | “Recombinant COVID-19 vaccine” NCT05124561 ↗ |
| Route | Inhaled | “Nebulized inhalation through the mouth” NCT05124561 ↗ |